The Lancet Oncology
Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial
By Stefanie Weigel, Hans-Werner Hense, Veronika Weyer-Elberich, Show 14 more authorsTOSYMA Screening Trial Study Group
Randomised trial in 99,558 peopleInterventions
24 months, multicentre, registered NCT03377036
- Digital breast tomosynthesis plus synthesised two-dimensional mammography
- Invasive interval breast cancers
- Humans
The paper
University of Münster and University Hospital Münster
The Lancet Oncology, 9 Oct 2026
